The Stockland Corporation Ltd (ASX: SGP) share price is in focus as the company announces an estimated distribution of 16.2 cents per security for the second half of FY26, bringing the full year payout to 25.2 cents, matching previous guidance.

What did Stockland report?

• Estimated 2H26 distribution: 16.2 cents per Ordinary Stapled Security
• FY26 full year distribution: 25.2 cents per Ordinary Stapled Security
• Distribution Record Date: 30 June 2026
• Payment Date: 31 August 2026
• Distribution Reinvestment Plan (DRP) will not operate for this period

What else do investors need to know?

Stockland has confirmed that the full-year distribution is in line with its prior guidance, offering stability for investors. The Distribution Reinvestment Plan (DRP) won’t apply for the 2H26 distribution, so any previous DRP elections won’t be used this time. No action is needed unless securityholders want to change their nomination.

The company will release its full-year financial results and final distribution details on 19 August 2026. Securityholders can access DRP FAQs and rules at the Stockland Investor Centre for more information.

What’s next for Stockland?

Investors can look forward to the upcoming results announcement, which will provide more detail on Stockland’s financial performance for FY26. With the distribution matching guidance and the next update scheduled, Stockland continues to emphasise consistency in its investor communications and returns.

Decisions on the Distribution Reinvestment Plan for future periods will be communicated in due course, and investors are encouraged to review their nominations if necessary.

Stockland share price snapshot

Over the past 12 months, Stockland shares have declined 25%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 4% over the same period.

View Original Announcement

The post Stockland announces FY26 distribution and DRP update appeared first on The Motley Fool Australia.

More reading

• Reliance Worldwide closes Australian brass sites
• Transurban Group overhauls NSW toll enforcement, ditches paper notices
• Iluka Resources signs multi-year rare earths supply deal
• Up 1,700% and more, what’s next for these ASX 200 shares?
• 5 things to watch on the ASX 200 on Tuesday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Transurban Group (ASX: TCL) share price is in focus today after the company announced a comprehensive overhaul to its NSW toll enforcement process, including switching off toll notice administration fees and moving to digital notifications for unpaid tolls.

What did Transurban Group report?

• Agreement with NSW Government to digitise unpaid toll reminders via email and SMS
• Phased switch-off of paper toll notices and elimination of related administration fees from July 2026*
• Enhanced support for motorists experiencing financial hardship
• Changes tied to broader Toll Reform outcomes between concessionaires and the NSW Government
• Ongoing protection of Transurban and partner investment in Sydney’s $36 billion road network

What else do investors need to know?

Transurban, alongside its investment partners, worked closely with the NSW Government to revamp the state’s toll notice process, aiming for earlier and more direct engagement with motorists. The reforms promise not only operational efficiency—like reduced paper usage—but also improvements to the customer experience, with timely digital alerts and clearer pathways for those in financial difficulty.

The reforms’ implementation will depend on the finalisation of administrative arrangements with Transport for NSW and the conclusion of broader toll reform discussions. If all goes to plan, the digital system is expected to roll out in July 2026.

What did Transurban Group management say?

CEO Michelle Jablko said:

Digitising toll notices will result in a better customer experience and reduced operating costs. These changes are consistent with the Government’s commitment to respecting the value of existing contracts and the revenue of concessionaires and are contingent on broader toll reform outcomes.

What’s next for Transurban Group?

With the new digital enforcement process nearing implementation, Transurban is positioning itself for smoother and more efficient toll collection in NSW. Investors can expect to hear more as the company and government finalise system upgrades and the broader Toll Reform package.

For now, the transition marks the final stages towards a significant shake-up in how Sydney’s toll roads are managed. Transurban says these changes should benefit motorists, the NSW Government, and shareholders by protecting core investments and supporting simpler road use.

Transurban Group share price snapshot

Over the past 12 months, Transurban Group shares have risen 5%, slightly outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 4% over the same period.

View Original Announcement

The post Transurban Group overhauls NSW toll enforcement, ditches paper notices appeared first on The Motley Fool Australia.

More reading

• Reliance Worldwide closes Australian brass sites
• Stockland announces FY26 distribution and DRP update
• Iluka Resources signs multi-year rare earths supply deal
• Up 1,700% and more, what’s next for these ASX 200 shares?
• 5 things to watch on the ASX 200 on Tuesday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Transurban Group. The Motley Fool Australia has positions in and has recommended Transurban Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

ASX healthcare shares have tested investors’ patience in recent years.

Some former market favourites have fallen out of favour as growth expectations, margins, valuations, and sentiment have all been reassessed.

But healthcare is still one of the most attractive long-term sectors on the market.

Demand is supported by ageing populations, chronic disease, medical innovation, and the simple reality that people do not stop needing treatment when the economy slows.

Two ASX healthcare shares that could be worth buying with a long-term view are in this article.

CSL Ltd (ASX: CSL)

The first ASX healthcare share to look at is biotech giant CSL.

It has been through a difficult period, with investors becoming far more cautious on its earnings outlook and growth profile.

But it could be worth sticking with the company. CSL is a global leader in plasma therapies, with products used across areas such as immunology and haematology. It also has exposure to vaccines and iron deficiency through other parts of the group.

This gives the company a broad healthcare platform, rather than a single product or single treatment market.

The plasma business is particularly important. It requires collection centres, manufacturing expertise, regulatory approvals, scale, and deep relationships across healthcare systems. These are not easy advantages for competitors to replicate quickly.

That does not mean CSL will rebound immediately. Management still needs to restore confidence, improve execution, and prove that its earnings base can grow again. But for patient investors, this is where the opportunity may sit.

If CSL can stabilise its performance and return to sustainable earnings growth, the current period of weakness could eventually look like a major reset in a high-quality healthcare business.

ResMed Inc (ASX: RMD)

Another ASX healthcare share that could be a great long-term buy is ResMed.

It is a global leader in sleep apnoea treatment and connected respiratory care.

ResMed’s products help patients breathe better and manage sleep-related breathing disorders. This includes devices, masks, accessories, software, and digital tools that support ongoing treatment.

The long-term opportunity is significant. Sleep apnoea is significantly underdiagnosed in many markets, but awareness of sleep health continues to grow. As more people are tested and treated, demand for ResMed’s devices and consumables could continue expanding.

So, with its shares down heavily from their highs, now could be an opportune time to invest with a long term view.

Why patience is important

CSL and ResMed are very different companies, but they share some important qualities.

Both operate in global healthcare markets, both have built strong positions over many years, both provide products that address real medical needs, and both have the potential to benefit from long-term demand rather than short-term consumer trends.

The challenge is that healthcare investing often requires patience.

Earnings growth can be uneven, sentiment can change quickly, and operational setbacks can take time to fix. Investors who buy these shares need to be willing to look beyond the next result and focus on the quality of the businesses over a longer horizon.

For patient investors, that could make CSL and ResMed shares very interesting opportunities right now.

They may take time to recover, but their global market positions, healthcare exposure, and long-term demand drivers could make them great ASX shares to buy and hold for the years ahead.

The post Should I buy CSL and ResMed shares right now? appeared first on The Motley Fool Australia.

More reading

• 2 ASX shares tipped to grow 50% or more in the next 12 months
• 3 reasons why experts think CSL shares are a sell
• 3 ASX healthcare shares to sell despite signs of sector rebound
• Buy, hold, sell: Life360, Woodside, CSL shares
• Why CSL, Westpac, and this big-name ASX 200 share could be sells

Motley Fool contributor James Mickleboro has positions in CSL and ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.